Zoann Nugent1,2,3, Harminder Singh1,2,3, Laura E Targownik1,2, Charles N Bernstein1,2. 1. Department of Internal Medicine, Max Rady College of Medicine, University of Manitoba, Manitoba, Canada. 2. University of Manitoba IBD Clinical and Research Centre, Manitoba, Canada. 3. Cancer Care Manitoba, Winnipeg, Manitoba, Canada.
Abstract
BACKGROUND: We aimed to report the rates of herpes zoster infection (HZI) before and after the introduction of herpes zoster vaccine (HZVac) and to determine the rates of HZVac after it became available in Manitoba in 2009. METHODS: We used the population-based University of Manitoba IBD Epidemiology Database to identify cases of inflammatory bowel disease (IBD) and controls (1984-2016) who were diagnosed with HZI before and after 2009 and to determine the rate of HZVac in those older than age 50 years. Further, we explored predictors of receipt of HZVac among persons with IBD. RESULTS: Persons with IBD vs matched controls have higher rates of HZI before diagnosis and postdiagnosis. HZI rates before 2009 per 1000 person-years were increased in persons with IBD (9.2) vs controls (7.2, P < 0.0001). Persons with IBD compared with controls were more likely to get HZVac (15.5 vs 12 per 1000 person-years). Persons newly diagnosed with IBD after 2009 and of higher socioeconomic status were more likely to get HZVac. Despite the introduction of HZVac, there was a steady rise in HZI throughout the study period (annual percent change in infection rates of +0.54, P < 0.0001). CONCLUSIONS: The increased risk of HZI in IBD may reflect an inherent risk associated with the disease or, in those already diagnosed, an increased risk secondary to the use of immunomodulating drugs. HZVac rates are very low, which may reflect physician and patient knowledge of the vaccine's availability and utility and the fact that it is not covered by the provincially provided health care plan.
BACKGROUND: We aimed to report the rates of herpes zoster infection (HZI) before and after the introduction of herpes zoster vaccine (HZVac) and to determine the rates of HZVac after it became available in Manitoba in 2009. METHODS: We used the population-based University of Manitoba IBD Epidemiology Database to identify cases of inflammatory bowel disease (IBD) and controls (1984-2016) who were diagnosed with HZI before and after 2009 and to determine the rate of HZVac in those older than age 50 years. Further, we explored predictors of receipt of HZVac among persons with IBD. RESULTS:Persons with IBD vs matched controls have higher rates of HZI before diagnosis and postdiagnosis. HZI rates before 2009 per 1000 person-years were increased in persons with IBD (9.2) vs controls (7.2, P < 0.0001). Persons with IBD compared with controls were more likely to get HZVac (15.5 vs 12 per 1000 person-years). Persons newly diagnosed with IBD after 2009 and of higher socioeconomic status were more likely to get HZVac. Despite the introduction of HZVac, there was a steady rise in HZI throughout the study period (annual percent change in infection rates of +0.54, P < 0.0001). CONCLUSIONS: The increased risk of HZI in IBD may reflect an inherent risk associated with the disease or, in those already diagnosed, an increased risk secondary to the use of immunomodulating drugs. HZVac rates are very low, which may reflect physician and patient knowledge of the vaccine's availability and utility and the fact that it is not covered by the provincially provided health care plan.
Authors: Christine N Manser; Michel H Maillard; Gerhard Rogler; Philipp Schreiner; Florian Rieder; Silja Bühler Journal: Digestion Date: 2020-01-22 Impact factor: 3.216
Authors: Jennifer L Jones; Frances Tse; Matthew W Carroll; Jennifer C deBruyn; Shelly A McNeil; Anne Pham-Huy; Cynthia H Seow; Lisa L Barrett; Talat Bessissow; Nicholas Carman; Gil Y Melmed; Otto G Vanderkooi; John K Marshall; Eric I Benchimol Journal: J Can Assoc Gastroenterol Date: 2021-07-29